Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Group 1 - Nektar Therapeutics closed an underwritten public offering of $115 million, selling 4,893,618 shares at a price of $23.50 per share [1][2] - The offering included 638,298 shares sold due to the underwriters' full exercise of their option to purchase additional shares [1] - The gross proceeds from the offering are approximately $115 million before deducting underwriting discounts and commissions [1] Group 2 - Nektar plans to use the net proceeds for general corporate purposes, including research and development, clinical development, and manufacturing costs [2] - Jefferies and Piper Sandler acted as joint bookrunning managers, with BTIG, LLC and H.C. Wainwright & Co. also involved in the offering [2] Group 3 - The securities were offered under a shelf registration statement filed with the SEC on March 28, 2025, and declared effective on April 1, 2025 [3] - A final prospectus supplement related to the offering is available on the SEC's website [4] Group 4 - Nektar Therapeutics is focused on developing treatments for autoimmune and chronic inflammatory diseases, with its lead product candidate being rezpegaldesleukin (REZPEG, or NKTR-358) [6] - The company is evaluating several drug candidates, including NKTR-255, an investigational IL-15 receptor agonist designed to enhance the immune system's ability to fight cancer [6]